Abstract
Multiple myeloma is the second most common hematological malignancy in adults, accounting for 2% of all cancer-related deaths in the UK. Current chemotherapy-based regimes are insufficient, as most patients relapse and develop therapy resistance. This review focuses on current novel antibody- and aptamer-based therapies aiming to overcome current therapy limitations, as well as their respective limitations and areas of improvement. The use of computer modeling methods, as a tool to study and improve ligand-receptor alignments for the use of novel therapy development will also be discussed, as it has become a rapid, reliable and comparatively inexpensive method of investigation.
Original language | English |
---|---|
Pages (from-to) | 705-722 |
Number of pages | 18 |
Journal | Therapeutic Delivery |
Volume | 12 |
Issue number | 10 |
Early online date | 27 Sept 2021 |
DOIs | |
Publication status | Published - 31 Oct 2021 |
Keywords
- review
- antibody–drug conjugates
- antibody therapy
- aptamer–drug conjugates
- aptamer therapy
- molecular docking
- multiple myeloma
- nanoparticles